Background. Approximately 35% of the North American population and an estimated 90% of the sub-Saharan African population have antibodies against adenovirus serotype 5 (AdHu5) that are capable of neutralizing AdHu5-based vaccines. In mice, intranasal delivery of AdHu5 expressing the Zaire ebolavirus glycoprotein human adenovirus serotype 5 (Ad) containing the genes for the Zaire ebolavirus glycoprotein (ZGP) under the expressional control of a cytomegalovirus immediate early promoter (CMV)) can bypass systemic preexisting immunity, resulting in protection against mouse-adapted Zaire ebolavirus (Mayinga 1976).
Ebola virus is a highly virulent infectious pathogen responsible for high mortality rates in humans reaching up to 90% [1] . The serious socioeconomic impact on communities affected by natural Ebola virus outbreaks and the potential to use this virus as a bioterrorism agent makes vaccine development a priority [2] . Although significant progress has been made in understanding the pathogenesis of Ebola virus infection, there is still no available licensed Ebola virus vaccine. However, several promising vaccine platform candidates that have proven efficacious against lethal Ebola virus infection in several animal models have been developed in recent years. These include virus-like particle preparations [3] [4] [5] [6] , vesicular stomatitis virus [7] [8] [9] [10] [11] , human parainfluenza virus type 3 [12] [13] [14] , and replication-deficient human adenovirus serotype 5 vectors [15] [16] [17] [18] [19] 
expressing Ebola virus gene(s).
Human adenovirus serotype 5 (AdHu5) is well characterized. It causes only mild respiratory disease, gastroenteritis, and conjunctivitis in humans while inducing a strong innate and adaptive immune response, making adenovirus (Ad)-based vectors an attractive vaccine platform [20] . Recombinant adenoviruses carrying antigens for bacteria (anthrax, plague) or viruses (hepatitis C, rabies, severe acute respiratory syndrome) have been shown to elicit strong immune responses against these pathogens [21, 22] . Recombinant adenoviruses expressing the Ebola virus glycoprotein (AdHu5-GP) mixed with AdHu5 expressing the Ebola virus nucleoprotein offered complete protection in nonhuman primates against lethal Ebola virus challenge [18, 19] . Such successes have encouraged the development of more replication-deficient adenovirus-based vaccine strategies and have led to a phase I clinical trial (http://clinicaltrials.gov/show/ NCT00374309) [23] .
An issue associated with AdHu5-based vaccines is that an estimated 35% of North American and as high as 90% of sub-Saharan African and Southeast Asian populations have evidence of previous exposure to AdHu5 reported by the detection of anti-AdHu5 antibodies, capable of neutralizing AdHu5-based vaccines [24, 25] . Preexposure to AdHu5 leading to detrimental preexisting immunity to AdHu5-based vaccine efficacy can be circumvented by different approaches. One is to substantially increase the adenoviral vector dose [26] . Another is the use of rare human serotypes such as AdHu12, AdHu35 [27] , and AdHu6 [28] or adenoviruses from other species such as simian [29] , bovine [30] , or porcine, which all have been shown to be promising tools to bypass preexisting immunity to AdHu5. Formulation modification by covalent attachment of polyethylene glycol to the surface of AdHu5 vaccines has also been successful in circumventing AdHu5 immunity [31] [32] [33] [34] . While several of these methods are promising, they still require further investigation to confirm their safety and practicality for large-scale production.
Currently, intramuscular injection is the primary method of administration of Ebola virus vaccines, which typically stimulate systemic responses [10, 19, 35] . Alternatively, mucosal vaccination is capable of inducing both mucosal and systemic immune responses [36, 37] . Mucosal vaccination has also been shown in mice to overcome preexisting systemic immunity to the vaccine carrier from prior exposure through natural infections or prior vaccinations [38, 39] .
AdHu5-GP was previously shown to protect mice, guinea pigs, and nonhuman primates from an otherwise lethal challenge of Zaire ebolavirus (ZEBOV) when administered via the intramuscular route [19, 40] . This first-generation vaccine was also proven to be efficacious in the mouse animal model when administered intranasally in the presence or absence of systemic adenoviral preexisting immunity [15, 16] . Several modifications to the antigenic expression cassette performed to improve expression levels of the ZGP (Zaire ebolavirus glycoprotein) antigen [generating human adenovirus serotype 5 (Ad) containing the genes for a gene optimized (opt) Zaire ebolavirus glycoprotein (ZGP) under the expressional control of a promoter that consists of a combination of the cytomegalovirus early enhancer element and chicken beta-actin promoter (CAG) (Ad-CAGoptZGP)] resulted in substantially improved T and B cell responses as well as protection in mice at doses 10-to 100-fold lower than those needed with the firstgeneration AdHu5-GP [17] . The primary goal of the present study was to test the hypothesis that intranasal administration of an Ad5-based Ebola virus vaccine can circumvent preexisting systemic immunity and confer full protection upon challenge in the guinea pig model of Ebola virus infection. Additionally, we wished to compare the first-and second-generation Ad-based Ebola virus vaccines' efficacy when administered either systemically or nasally in the presence or absence of systemic or mucosal preexisting immunity to adenovirus.
MATERIALS AND METHODS

Construction and Production of Adenoviral Vaccine
The construction of the improved expression cassette was described previously [17, 29] . Particle number and infectivity were determined by optical density and immunodetection of the hexon protein (Adeno-X rapid titer kit, Clontech). Adenovirus preparations were generated and quantified for both infectious and total particle numbers.
Animal Models, Vaccination, and Challenge
Hartley guinea pigs (Charles River) were used to evaluate protection and antibody immune response against AdHu5 hexon proteins and ZGP. Groups of 6-9 guinea pigs were given 1 3 10 11 total viral particles of recombinant AdHu5 containing lacZ genes intranasally or intramuscularly to induce an immune response against adenovirus. Twenty-eight days later these guinea pigs were vaccinated either intranasally or intramuscularly with 1 3 10 10 total viral particles of either human adenovirus serotype 5 (Ad) containing the genes for the Zaire ebolavirus glycoprotein (ZGP) under the expressional control of a cytomegalovirus immediate early promoter (CMV) (Ad-CMVZGP) or human adenovirus serotype 5 (Ad) containing the genes for a gene optimized (opt) Zaire ebolavirus glycoprotein (ZGP) under the expressional control of a promoter that consists of a combination of the cytomegalovirus early enhancer element and chicken betaactin promoter (CAG) (Ad-CAGoptZGP) vaccine. Vaccines used in this study were derived from 1 preparation of either Ad-CAGoptZGP or Ad-CMVZGP and these preparations had a comparable noninfectious to infectious ratio of 48:1 and 128:1, respectively. Vaccinations were administered intramuscularly or intranasally using 200 lL of recombinant adenoviral vector diluted in phosphate-buffered saline (PBS). Guinea pigs were challenged 28 days after vaccination by intraperitoneal injection with 1000 LD 50 (median lethal dose where the treatment will be lethal to 50% of the population) of guinea pig-adapted ZEBOV [41] .
Antiadenovirus Serotype 5-Neutralizing Antibodies
Preexisting immunity against recombinant AdHu5 was assessed by determining the amount of neutralizing antibody (NAb) present in serum or nasal wash according to established methods [15] . determine immunoglobulin G (IgG) and immunoglobulin A (IgA) levels in serum, and nasal washes, 96-well plates were coated with 1 lg/mL of ZEBOV-GPDTM-HIStag protein as previously described [43] . Guinea pig serum samples were diluted 1:50. Secondary antibody was diluted at 1:1000 (peroxidase-labeled affinity purified antibody to guinea pig IgG [H + L]); Kirkegaard & Perry Laboratories, Inc.
[KPL]). ABTS Peroxidase Substrate System (KPL) was used for detection and data were collected using an ASYS UVM 340 ELISA plate reader (Isogen Life Science) at optical density measured by absorbance at 405 nanometers.
Statistical Analysis
Data were analyzed for statistical differences by performing 1-way analysis of variance (ANOVA, Tukey-Kramer multiple comparisons test) or repeated-measures ANOVA when appropriate. The differences in the mean or raw values among treatment groups were considered significant when P , .05.
RESULTS
Effect of Systemic or Nasal Immunization on B Cell Responses to the Ebola Virus Glycoprotein in Guinea Pigs With or Without Preexisting Immunity to Adenovirus
In an effort to correlate markers of immunity with protection against Ebola virus infection after nasal vaccination, antibody , nasal wash and serum sample collection day -31 and day -3 (white circles) and challenge day (grey circles) are shown. Groups of 6 to 9 guinea pigs were used for these assays. The route of administration and the vaccine used are shown for each group (circle with horizontal lines). 1x10 10 total particles per guinea pig was the vaccination dose for both Ad-CMVZGP and Human adenovirus serotype 5 (Ad) containing the genes for a gene optimized (opt) Zaire ebolavirus glycoprotein (ZGP) under the expressional control of a promoter that consists of a combination of the cytomegalovirus early enhancer element and chicken beta-actin promoter (CAG) treatments regardless of the route of administration. Animals were monitored daily for clinical signs of illness days 1-21 (circle with vertical lines).
immune responses against Ebola virus glycoprotein were analyzed in guinea pigs in the presence or absence of induced preexisting immunity to adenovirus 25 days after vaccination. Preexisting immunity was induced (as described in Materials and Methods) 28 days prior to vaccination with a first-generation adenovirus serotype 5 vector expressing the Zaire ebolavirus glycoprotein (Ad-CMVZGP) or an improved second-generation vaccine (Ad-CAGoptZGP) according to the schedule outlined in Figure 1 . In brief, guinea pigs were administered Ad-lacZ via the intramuscular or intranasal route or not at all for the positive controls. Twenty-eight days later each of these groups were vaccinated with either Ad-CMVZGP or Ad-CAGoptZGP via the intramuscular or intranasal route and challenged with guinea pig-adapted ZEBOV 28 days later (Figure 1 ). Both serum and nasal washes were collected from the guinea pigs 28 days after Ad-lacZ administration and analyzed for levels of NAb. Animals receiving Ad-lacZ intramuscularly had an average antiadenovirus circulating NAb titer from serum samples (reciprocal dilution) of 407 6 253 while those administered Ad-lacZ intranasally had lower NAb levels of 45 6 34 ( Figure 2A ). The titer of NAb detected in nasal washes was at the limit of detection of the assay at 6 6 2 and 14 6 6 for intramuscular and intranasal administration, respectively ( Figure 2B) . No detectable levels of NAb were observed for the nontreated groups for either the serum or nasal wash NAb assays (Figure 2A and 2B) .
Twenty-five days after vaccination, serum levels of NAb (against ZEBOV-GP) were determined for vaccinated animals to assess antibody responses as described in Materials and Methods. Naive guinea pigs vaccinated with Ad-CMVZGP via the intramuscular or intranasal route had levels of 70 6 14 or 28 6 3 reciprocal dilution of anti-ZGP NAb in the serum, respectively ( Figure 3A) . From the same animals vaccinated via the intramuscular or intranasal route, titers of 9 6 1 and 21 6 8 reciprocal dilution, respectively, were detected from the nasal washes ( Figure 3B ). Guinea pigs with systemically induced preexisting immunity vaccinated intramuscularly or intranasally with Ad-CMVZGP had anti-ZGP NAb of 60 6 25 and 20 6 8 reciprocal dilution, respectively ( Figure 3B ). Guinea pigs with mucosally induced preexisting immunity immunized intranasally with Ad-CMVZGP had an anti-ZGP NAb reciprocal dilution level of 20 6 7. Naive guinea pigs vaccinated with Ad-CAGoptZGP via either the intramuscular or intranasal route had 108 6 35 or 35 6 17 anti-ZGP reciprocal dilution NAb levels in the serum, respectively, and 7 6 0 or 17 6 7 reciprocal dilution from the nasal washes. Guinea pigs with systemically induced preexisting immunity given Ad-CAGoptZGP vaccine either intramuscularly or intranasally had NAb levels of 37 6 12 or 23 6 14, respectively. Guinea pigs with mucosally induced preexisting immunity vaccinated intranasally with Ad-CAGoptZGP had anti-ZGP NAb reciprocal dilution levels of 35 6 8. Anti-ZGP NAb could not be detected in samples from control guinea pigs ( Figure 3A and 3B) .
Characterization of Ebola virus glycoprotein-specific immunoglobulin isotypes obtained from serum was performed on guinea pigs vaccinated with either Ad-CMV-ZGP or AdCAGoptZGP by intramuscular injection. A decrease of 74% and 40% in the production of IgG in the presence of systemically induced preexisting immunity to adenovirus was observed following vaccination with either Ad-CMV-ZGP or AdCAGoptZGP, respectively ( Figure 4 ). Intranasal vaccination induced detectable IgG responses that for Ad-CMVZGP were reduced by 29% in the presence of preexisting immunity regardless of which route was used to induce preexisting immunity. Similarly, Ad-CAGoptZGP-vaccinated guinea pigs' IgG levels were decreased by 33% or 40% for guinea pigs with intranasally or intramuscularly induced immunity, respectively. Ebola virus glycoprotein-specific IgA was detected from nasal washes of guinea pigs immunized only intranasally, however, at levels around the limit of detection of the assay and therefore not reliable for comparative analysis (data not shown).
Effect of Nasal Vaccination on Survival Against Lethal Ebola Virus Challenge in the Presence of Preexisting Immunity
The most direct means of evaluating vaccine efficacy in guinea pigs is to assess protection by monitoring weight loss and death rates after a lethal challenge of Ebola virus [16] . Therefore, guinea pigs were immunized with 1 3 10 10 total viral particles of Ad-CMVZGP or Ad-CAGoptZGP by the intramuscular or intranasal route in the presence or absence of preexisting immunity. At the time of vaccination, guinea pigs immunized with Ad-lacZ intramuscularly had an average antiadenovirus-circulating NAb titer of 407 6 253 reciprocal dilution while those animals given Ad-lacZ intranasally had levels of 45 6 34. Naive guinea pigs vaccinated by intramuscular injection with PBS served as controls for complete lethality following challenge with guinea pigadapted Zaire ebolavirus (GA-ZEBOV). All control animals exhibited weight loss and succumbed to the disease by 8 days after infection ( Figure 5A and 5C). Similarly, guinea pigs in which preexisting immunity was induced to adenoviruses followed by intramuscular vaccination with Ad-CMVZGP vaccine also all succumbed by day 8 after challenge ( Figure 5A ). In contrast, naive guinea pigs given the vaccine survived challenge regardless of the route of immunization ( Figure 5A ), exhibiting little to no weight loss ( Figure 5B ). Guinea pigs with preexisting immunity administered systemically and vaccinated by the nasal route all survived the challenge ( Figure 5A ) with little to no weight loss ( Figure 5B ). Among guinea pigs with mucosally induced preexisting immunity and then vaccinated intranasally with Ad-CMVZGP, 5 of 6 animals survived and 1 animal exhibited persistently decreasing total weight resulting in death on day 20 after infection ( Figure 5A and 5B). Interestingly, survival following intramuscular or intranasal vaccination with Ad-CAGoptZGP in the presence of local preexisting immunity was higher than with Ad-CMVZGP in comparable conditions, presumably due to higher expression level of the antigen ZGP. Intramuscular vaccination with AdCAGoptZGP in the presence of systemic preexisting immunity led to a 78% survival rate and 100% after intranasal vaccination in the presence of nasally induced preexisting immunity. In a pilot study, guinea pigs with mucosally induced preexisting immunity given either vaccine showed no signs of disease and had complete survival (data not shown).
Prevalence of Adenoviral Immunity in Human Nasal Mucosa and Airway
The data presented above suggest that levels of preexisting immunity to adenovirus in the nasal cavity and airway could have an impact on the efficacy of an adenovirus-based vaccine administered nasally. In an effort to estimate the viability of this approach for use in humans, we evaluated 51 clinical samples collected from nasal washes and serum for the presence of 11 total viral particles of adenovirus serotype 5 expressing b-galactosidase (Ad-lacZ) 28 days prior to vaccination were also immunized in the same manner. Control guinea pigs were administered phosphatebuffered saline. A, Serum neutralizing antibody (Nab) levels against Zaire ebolavirus expressing enhanced green fluorescent protein (ZEBOV-EGFP) were evaluated 25 days after vaccination. B, Nasal wash NAb levels against ZEBOV-EGFP were evaluated 25 days after vaccination. In both panels, error bars represent the standard deviation of the data. naturally acquired NAb to adenovirus serotype 5. All samples were collected from patients with confirmed or clinically diagnosed influenza virus. Twenty-one of the 51 patients (41%) demonstrated significant levels of antiadenovirus NAb in the serum, with a reciprocal dilution ranging from 80 to greater than 2560 ( Figure 6A ). Individuals who tested positive for systemic immunity were also assayed for mucosal immunity. Nasal wash samples were tested for the presence of antibodies to adenovirus; 20 of 21 samples had levels close to the detection limit of the assay with a reciprocal dilution ranging from 2 to 12 ( Figure 6 ). The one mucosal sample where adenovirus-specific antibodies could not be detected also had the lowest serum level at a reciprocal dilution of 80 ( Figure 6A) .
A pool of 18 human bronchoalveolar lavage samples were also assayed, and antiadenovirus NAb was detected in 39% of the samples ( Figure 6B ). The reciprocal dilution values ranged from 4 to 18 with one sample at 49 ( Figure 6B ). Corresponding serum samples that were successfully obtained from 9 of the individuals showed that 5 were positive for antiadenovirus antibodies ranging from 53 to greater than 2560 reciprocal dilution ( Figure 6D ), again indicating that systemic levels of NAb to adenovirus serotype 5 are substantially higher than levels in the nasal mucosa and airway.
DISCUSSION
Natural transmission of Ebola virus occurs through direct contact with body fluids of infected individuals and as such may also involve the mucosa as a route of exposure. For this reason growing efforts are being made to also target the mucosa for vaccination [15, 44] . The mucosa-associated lymphoid tissues produce approximately 80% of all immunocytes [45, 46] . It has been shown that administration of a vaccine by different routes can have a significant effect on the type and strength of the induced immune response [36, 37] . Intramuscularly administered vaccines typically stimulate systemic responses, whereas mucosal vaccination induces both systemic and mucosal immune responses, however, at reduced levels overall [10, 19, 35, 45] . The data presented here appear to be consistent with these reports as the NAb level against Ebola virus glycoprotein detected in the serum was lower for nasally immunized animals than that following systemic vaccination with either Ad-CMVZGP or Ad-CAGoptZGP. Nasal vaccination did, however, generate detectable antibody responses in the nasal mucosa in Ad-CMVZGP-or Ad-CAGoptZGP-vaccinated guinea pigs. Interestingly, IgG levels in the serum of nasally vaccinated guinea pigs were comparable to those from systemically vaccinated animals for both Ad-CMVZGP and Ad-CAGoptZGP (Table 1) . Additionally, a single intranasal vaccination with either Ad-CMVZGP or Ad-CAGoptZGP protected 100% of guinea pigs with little to no signs of disease after challenge with 1000 LD 50 of GA-ZEBOV even in the presence of systemically induced antiadenovirus immunity. Even though some animals did not show signs of clinical symptoms following the Ebola virus challenge, some level of active Ebola virus replication cannot be ruled out at this point. Additional experiments monitoring viral loads and developing immune responses following challenge will be necessary. Overall, intranasal vaccination appears to be a viable method of vaccination in the guinea pig model of Ebola infection in addition to the murine model.
Mucosal vaccination using adenovirus-based vaccine platforms has now been shown to confer protection from a variety of pathogens in the presence of preexisting immunity to the vaccine vector in several animal models [15, [47] [48] [49] [50] . This level of protection is achieved even with overall reduced levels of NAb when compared to the intramuscular route. Interestingly, the level of systemic anti-Ebola virus glycoprotein antibodies was significantly reduced following intramuscular vaccination with Ad-CAGoptZGP in the presence of preexisting immunity but Preexisting immunity to the adenoviral backbone of Ad-based vaccines can be bypassed by increasing the dose of the Ad-based vaccine administered [26] . Vaccination with Ad-CMVZGP administered intramuscularly in the presence of preexisting immunity could not protect guinea pigs against lethal challenge with Ebola virus even with an immunization dose of 1 3 10 10 total particles per animal. Interestingly, partial protection was observed using Ad-CAGoptZGP at the same total particle dose, confirming that higher antigenic expression can contribute to overcome preexisting immunity. It is also noteworthy that despite elevated systemic levels of circulating antiadenoviral antibodies in either guinea pigs or humans, the levels of corresponding mucosal neutralizing antibodies were relatively low. Overall, this is consequent with the short half-life of mucosal antibody and the idea that mucosal immunity may not be as robust and long-lasting as systemic immune responses.
While there have been many studies reporting the seroprevalence to AdHu5 in the general human population of different continents, there are relatively little data on antibody levels and prevalence against AdHu5 in the mucosa and airway [15] . In our study, among the 51 individuals tested for antiadenovirus antibody from serum and nasal wash samples, 41% had detectable antibody in the serum including some relatively high (above 1:2500), whereas corresponding antiAdHu5 antibody in nasal samples remained low overall (below 1 :20) . Bronchoalveolar lavage samples also demonstrated the presence of mucosal antiadenovirus antibodies in 39% of the samples, which is consistent with the predicted 35% to 40% of seroprevalence in the North American population [24, 25] . However, comparison of systemic and mucosal antiadenovirus antibody levels reveals that levels are substantially lower in both nasal wash and bronchoalveolar lavage samples in corresponding patients. These lower levels of antiAdHu5 antibodies also detected in the nasal mucosa of intranasally immunized guinea pigs may explain the successes observed after vaccination and challenge.
The present work shows that intranasal vaccination with an adenovirus-based vaccine can induce a protective immune response against a systemic lethal challenge with guinea pig-adapted Ebola virus with or without preexisting immunity to AdHu5. These results are encouraging, but further evaluation and characterization of the immune response in relation to the route of vaccination and the route of challenge are important. Furthermore, when repeating these experiments in nonhuman primates, a more relevant animal species to model human Ebola virus infection is essential to fully evaluate the potential of this approach. The present study mainly monitored the antibody response to document the immune response, as molecular tools are not available to evaluate the T cell immune response in guinea pigs. Cellular and humoral immune responses following adenovirus-based Ebola vaccine administration were documented in mice in the presence or absence of preexisting immunity [15] . Although no true immune correlates of protection against Ebola virus infection have been identified, the accumulation of data on available immune parameters from survivors and nonsurvivors should be of value to the development of protective measures against filovirus infection. Additional studies Ad-based vaccine candidates will also be useful to assess the full impact of preexisting immunity on vaccine potency. Defining the influence that preexisting immunity has on naturally acquired or adenoviral vaccine-induced immunity will help further develop adenovirus-based vaccines and better estimate their utility in animals and humans.
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